Discussion
Clinical trials of UX-DA003, an experimental stem cell therapy for Parkinson’s disease developed by Unixell Biotechnology, can now begin in the U.S. following clearance from the Food and Drug Administration (FDA). The therapy aims to replace dopaminergic neurons, which are the nerve cells lost in Parkinson’s. It uses…
